Sonoma Pharmaceuticals (SNOA) Gains from Sales and Divestitures (2016 - 2025)
Sonoma Pharmaceuticals (SNOA) recorded quarterly Gains from Sales and Divestitures of $9538.0 in Q1 2025, little changed quarter-over-quarter from $9538.0 in Q4 2024, and down 96.2% on a YoY basis from $251000.0 in Q1 2024.
Sonoma Pharmaceuticals (SNOA) Gains from Sales and Divestitures (2016 - 2025) Analysis & Trends
Sonoma Pharmaceuticals' Gains from Sales and Divestitures history runs 10 years deep, the most recent figure standing at $9538.0 for Q1 2025.
- In Q1 2025, Gains from Sales and Divestitures fell 96.2% year-over-year to $9538.0; the TTM figure through Mar 2025 stood at $9538.0 (down 96.2% YoY), while the FY2025 annual figure was $9538.0, down 96.2% from the prior year.
- Gains from Sales and Divestitures was $9538.0 for Q1 2025 at Sonoma Pharmaceuticals, roughly flat from $9538.0 in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $251000.0 in Q4 2023 to a low of $833.0 in Q3 2021.
- Historically, Gains from Sales and Divestitures has averaged $92014.0 across 5 years, with a median of $9538.0 in 2024.
- Biggest YoY gain for Gains from Sales and Divestitures was 1959.57% in 2024; the steepest drop was 96.2% in 2024.
- A 5-year view of Gains from Sales and Divestitures shows it stood at $833.0 in 2021, then soared by 191.6% to $2429.0 in 2022, then jumped by 10233.47% to $251000.0 in 2023, then tumbled by 96.2% to $9538.0 in 2024, then changed by 0.0% to $9538.0 in 2025.
- The last three Gains from Sales and Divestitures figures came in at $9538.0 (Q1 2025), $9538.0 (Q4 2024), and $9538.0 (Q3 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | Sonoma Pharmaceuticals | 1.90 Mn | -659,569.98 | 1.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 9,538.00 |
| Mar 31, 2025 | 9,538.00 |
| Dec 31, 2024 | 9,538.00 |
| Dec 31, 2024 | 9,538.00 |
| Sep 30, 2024 | 9,538.00 |
| Sep 30, 2024 | 9,538.00 |
| Jun 30, 2024 | 190,758.00 |
| Jun 30, 2024 | 190,758.00 |
| Mar 31, 2024 | 251,000.00 |
| Mar 31, 2024 | 251,000.00 |
| Dec 31, 2023 | 251,000.00 |
| Dec 31, 2023 | 251,000.00 |
| Sep 30, 2023 | 244,000.00 |
| Sep 30, 2023 | 244,000.00 |
| Jun 30, 2023 | 208,000.00 |
| Jun 30, 2023 | 208,000.00 |
| Mar 31, 2023 | 12,187.00 |
| Mar 31, 2023 | 12,187.00 |
| Mar 31, 2022 | 2,429.00 |
| Mar 31, 2022 | 2,429.00 |